<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C60CE47-6ED7-4C38-BF0D-BEE689253646"><gtr:id>9C60CE47-6ED7-4C38-BF0D-BEE689253646</gtr:id><gtr:name>Servier Laboratories</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BA0399FB-55F2-4341-9E16-5F6C90F98AEA"><gtr:id>BA0399FB-55F2-4341-9E16-5F6C90F98AEA</gtr:id><gtr:name>Cara Therapeutics</gtr:name><gtr:address><gtr:line1>1 Parrott Dr</gtr:line1><gtr:line2>34 Spruce Street</gtr:line2><gtr:postCode>CT 06484</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C60CE47-6ED7-4C38-BF0D-BEE689253646"><gtr:id>9C60CE47-6ED7-4C38-BF0D-BEE689253646</gtr:id><gtr:name>Servier Laboratories</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BA0399FB-55F2-4341-9E16-5F6C90F98AEA"><gtr:id>BA0399FB-55F2-4341-9E16-5F6C90F98AEA</gtr:id><gtr:name>Cara Therapeutics</gtr:name><gtr:address><gtr:line1>1 Parrott Dr</gtr:line1><gtr:line2>34 Spruce Street</gtr:line2><gtr:postCode>CT 06484</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/48C13E55-28C1-4AE4-BA67-521BE128FE74"><gtr:id>48C13E55-28C1-4AE4-BA67-521BE128FE74</gtr:id><gtr:firstName>Graeme</gtr:firstName><gtr:surname>Milligan</gtr:surname><gtr:orcidId>0000-0002-6946-3519</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9811527"><gtr:id>1E794361-0128-442B-9DBF-202CBA828429</gtr:id><gtr:title>The quaternary structure of G protein-coupled receptors: implications for function and drug design</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9811527</gtr:grantReference><gtr:abstractText>Efforts to develop effective and novel small molecule medicines attract considerable interest from the public as well as from the scientific community. Medicines targeted at GPCRs are used very widely. Although the U.K. public are, in general, less well informed than their American counterparts, there is widespread recognition of the Product names of many of these medicines including a variety of anti-histaminergics and anti-hypertensive drugs. Dissemination of information produced from these studies will concentrate on traditional routes such as publication of articles in peer-reviewed Journals and the presentation of talks to informed audiences. I have published more than 350 articles and give some 15-20 lectures furth of Glasgow each year. However, I also plan to present public lectures related to my work to groups, including school children and junior undergraduate students to extend their knowledge base. The Glasgow Science centre and the outreach programmes of Glasgow University offer excellent opportunities to enhance public understanding of science. I have also previously been involved with presentations at the Edinburgh Science Festival and my position as a Fellow of the Royal Society of Edinburgh offers further opportunities as this is a central remit of the Society.</gtr:abstractText><gtr:technicalSummary>G protein-coupled receptors (GPCRs) are the most tractable set of targets for the development of clinically effective, small molecule medicines. There is thus great interest in their structure, regulation and activation mechanisms. Data mining of genome sequencing programmes indicate that at least 380 genes in man encode GPCRs likely to be activated by endogenously produced regulators. It is becoming increasingly clear that GPCRs do not function as monomers but possess quaternary structure. Widespread co-expression of many GPCR gene products implies that individual GPCRs with significiant mutual affinity will have the potential to exist as hetero-dimers/oligomers as well a homo-dimers/oligomers. This programme of work will explore both the fundamental mechanisms that contribute to GPCR dimerisation and its selectivity and will study the details of hetero-dimeric interactions between pairs of GPCRs with physiologically relevant co-expression patterns where preliminary data indicates that their interactions alter function and/or pharmacology. Supported by grant G9811527 I developed the use of GPCR-G protein fusions. The GPCR-G protein fusion strategy offers an ideal means to examine the basis, selectivity and mechanisms of function of GPCR dimers. It also offers a highly novel means to monitor the function and potentially unique pharmacology only of hetero-dimers that form following expression of two different GPCRs. This approach will be supplemented by use of resonance energy transfer techniques and the ability of co-expressed fragments of GPCRs to reconstitute or to interfere with function. The programme of work will provide unique insights into the quaternary structure of the largest family of transmembrane signalling proteins and may have profound implications for the identification of novel therapeutic small molecules.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1638140</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cara Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>screening for heterodimer selective ligands. Relevance to pain and inflammation</gtr:description><gtr:id>AFA78BB8-756F-452A-A78E-B08157878BE6</gtr:id><gtr:impact>This is NOT directly related to the work in the programme but the work performed in the programme resulted in interest in the potential for novel aspects of drug discovery that was supported by a research contract from Cara Therapeutics. This has expanded our efforts in the general area of G-protein-coupled receptor dimerisation and the concept that receptor hetero-dimers may be novel targets for therapeutic drugs.</gtr:impact><gtr:outcomeId>FBE9EA016A7-1</gtr:outcomeId><gtr:partnerContribution>Efforts to explore the potential for novel targets for therapeutic drugs. Funding, and access to non-commercially available receptor ligands</gtr:partnerContribution><gtr:piContribution>This is NOT directly related to the work in the programme but the work performed in the programme resulted in interest in the potential for novel aspects of drug discovery that was supported by a research contract from Cara Therapeutics. This has expanded our efforts in the general area of G-protein-coupled receptor dimerisation and the concept that receptor hetero-dimers may be novel targets for therapeutic drugs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Glaxo SmithKline Studentship Free Fatty Acid receptors</gtr:description><gtr:id>C39F9B85-317F-45D4-BCD4-2A8C1AF5E91D</gtr:id><gtr:impact>This is NOT directly related to the work in the programme but the work performed in the programme resulted in interest in the potential for novel aspects of drug discovery that was supported by a studentship from GSK. This has expanded our efforts in the general area of G-protein-coupled receptor dimerisation.</gtr:impact><gtr:outcomeId>750699DB830-1</gtr:outcomeId><gtr:piContribution>I was PI for the CASE studentship</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Servier Laboratories</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Dopamine D2/ dopamine D3 receptor interactions</gtr:description><gtr:id>F8E25E40-09B4-4FD3-BB37-769CEB54041D</gtr:id><gtr:impact>No publications have yet emerged from this work</gtr:impact><gtr:outcomeId>7777B02EC76-1</gtr:outcomeId><gtr:partnerContribution>Contract research</gtr:partnerContribution><gtr:piContribution>Efforts to explore the potential for novel targets for therapeutic drugs. Funding, and access to non commercially available receptor ligands</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talks at International meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B24F78B-C814-4B89-B6AC-72AF30CAB033</gtr:id><gtr:impact>I give a large number of seminars at conferences, at University departments and to Pharmaceutical/biotechnology companies. One I have listed the date above for was 'Novel Assay Technologies for the Discovery of GPCR Drugs&amp;quot;, Screening Europe Conference, Barcelona, Spain. Keynote Presentation

In in the perio 2008-2013 I have given more than 50 such presentations

Press conference</gtr:impact><gtr:outcomeId>9538D47599C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to Industry meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9E23BC4A-DA92-4A2F-8173-80C863998939</gtr:id><gtr:impact>Approx 200 researchers predominantly from the Pharma/Biotech sector attend annually a series of meetimngs at the interface of industrial and academic research in this area.

I was subsequently invited to discuss issues and topics arising by a number of Pharma companies</gtr:impact><gtr:outcomeId>QngQqVSKfUn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1784830</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3055B26F-FEA2-45FD-8707-492F3DE04872</gtr:id><gtr:outcomeId>9466A5F22E50</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>197433</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant (The molecular basis of cannabinoid CB1 receptor regulation of the sensitivity of orexin-1 receptor signalling)</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>F6F3C18B-F4A1-452F-91C5-31D66994552B</gtr:id><gtr:outcomeId>9FE1BB27B490</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>254635</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Servier Laboratories Ltd., Research Contract</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Servier Laboratories</gtr:fundingOrg><gtr:id>1365AA5F-D8A2-4C7E-87F6-15769E0D78C4</gtr:id><gtr:outcomeId>48D384BAC7F0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>416349</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant (Exploring the selectivity and consequences of GPCR homo and hetero- dimerisation/oligomerisation using RASSLs)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>EA34F304-6A81-40C4-A2AC-99D2C2EF4D00</gtr:id><gtr:outcomeId>FE539E6C1C40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This is a technology application deriving from both MRC and BBSRC funding to allow the development of a screening platform fo the identification of ligands with affinity and seelctivity for GPCR heteromers.</gtr:description><gtr:grantRef>G9811527</gtr:grantRef><gtr:id>CFC59893-7466-4161-9001-76DE9EA9A5F0</gtr:id><gtr:impact>The technology remains an integral part of the basic research portfolio of my team</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>23965EEE6C8</gtr:outcomeId><gtr:patentId>US2008286828</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Dimer-Screen Technology</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member Nomenclature committee-International Union of Basic and Clinical Pharmacology</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>5705278D-5420-459D-B067-4CE98D5B5CA5</gtr:id><gtr:outcomeId>55FE31E3F22</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The G Protein Coupled Receptor Oligomer Knowledge Base.</gtr:description><gtr:id>23A0A688-E712-4DFA-BD54-B1E3BE3F1C66</gtr:id><gtr:impact>This is dificult to assess. Rapid expansion of available data about G Protein Coupled Receptor (GPCR) dimers/oligomers over the past few years requires an effective system to organize this information electronically. Based on an ontology derived from a community dialogue involving colleagues using experimental and computational methodologies, we developed the GPCR-Oligomerization Knowledge Base (GPCR-OKB). GPCR-OKB is a system that supports browsing and searching for GPCR oligomer data. Such data were manually derived from the literature. While focused on GPCR oligomers, GPCR-OKB is seamlessly connected to GPCRDB, facilitating the correlation of information about GPCR protomers and oligomers. Availability and Implementation: The GPCR-OKB web application is freely available at http://www.gpcr-okb.org</gtr:impact><gtr:outcomeId>awz3fR3SUNZ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GPCR-OKB:</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://www.gpcr-okb.org</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Links a G protein-coupled receptor to a G protein to produce a single open reasding frame incorporating both functionalities</gtr:description><gtr:id>FA066247-53D5-4EA1-8871-235338572CBE</gtr:id><gtr:impact>Used in drug screening and a variation of this resulted in the submission of a patent that has bene licensed by two pharmaceutical companies</gtr:impact><gtr:outcomeId>CE5DEC0C9BB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GPCR-G protein fusions</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines that stably express or can be induced to express G protein-coupled receptors linked to a suitable reporter gene, this may be a fluorescent polypeptide, e.g. GFP or a enzyme e.g. luciferase.</gtr:description><gtr:id>D952A9D5-1D58-4DBB-A7FD-757B4AD86151</gtr:id><gtr:impact>Such reagents/cells lines are used widely in academic research, and in drug screening.</gtr:impact><gtr:outcomeId>9D99A0D2921</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Flp-In cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Cara Therapeutics</gtr:companyName><gtr:description>The compnay seeks novel tratments in the areas of pain and inflammation. Currently the most advanced programme is in 'phase II' clinical trials.
http://www.caratherapeutics.com/</gtr:description><gtr:id>F951FDDC-9C4B-4565-9B3A-BED4FD6887F9</gtr:id><gtr:impact>Until the clinical trials are complete the impact cannot be assessed.</gtr:impact><gtr:outcomeId>SzZBpDKtqXH</gtr:outcomeId><gtr:url>http://www.caratherapeutics.com/</gtr:url><gtr:yearCompanyFormed>2007</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>D610C7C4-FE31-4A7D-83BE-BF1CFC6AC6B4</gtr:id><gtr:title>Selectivity and functional consequences of interactions of family A G protein-coupled receptors with neurochondrin and periplakin.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca60e302065b8bcff5997ea08ec5c15"><gtr:id>4ca60e302065b8bcff5997ea08ec5c15</gtr:id><gtr:otherNames>Ward RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>CE0215C7599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDD11BD2-93B4-41E1-A64A-FA7B9BEE1D4C</gtr:id><gtr:title>The role of dimerisation in the cellular trafficking of G-protein-coupled receptors.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>ZsVQWsVvfpH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A2A09DB-302C-4210-ACD2-4E5DB4FA149A</gtr:id><gtr:title>Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/007b27bf0d80b1a0eb2b339032484e9c"><gtr:id>007b27bf0d80b1a0eb2b339032484e9c</gtr:id><gtr:otherNames>Lopez-Gimenez JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>C96CAA2A31E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD3F3B25-8D88-4A61-A241-D21D1B50455D</gtr:id><gtr:title>Identification of a serotonin/glutamate receptor complex implicated in psychosis.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a13187bbdb6ebc82aa6887c2159948af"><gtr:id>a13187bbdb6ebc82aa6887c2159948af</gtr:id><gtr:otherNames>Gonz?lez-Maeso J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>75E1EEE5934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35B7B918-E6F8-47D6-8EE6-A78044C10C4E</gtr:id><gtr:title>G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>38AECA3E103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9E54C2A-8981-4905-93BD-D02FC32739CA</gtr:id><gtr:title>Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective alpha(1b)-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfe83ef029eb561882dad7311aebc837"><gtr:id>dfe83ef029eb561882dad7311aebc837</gtr:id><gtr:otherNames>Canals M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>395BFE1EFBA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B202F6F-CBA2-4F9B-9744-26274F3E5A68</gtr:id><gtr:title>G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>1625023472D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D957E69C-5D45-4F2A-B450-750D417604E5</gtr:id><gtr:title>International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/391335dc526b1cfeba761243274591e4"><gtr:id>391335dc526b1cfeba761243274591e4</gtr:id><gtr:otherNames>Pin JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>0C69ABAF4C8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB0B62CF-F780-48A8-AA3D-DBA6F7433901</gtr:id><gtr:title>G protein-coupled receptor dimerisation: molecular basis and relevance to function.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>54BFE8F898F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67A8FDBE-65A9-43D9-A428-CFBE216DD21E</gtr:id><gtr:title>A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>10C79DE2340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E549D62-CB10-4B4E-B3B0-2F7388E4FB5D</gtr:id><gtr:title>Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d05b5a9775b711c5d24459949a4aed77"><gtr:id>d05b5a9775b711c5d24459949a4aed77</gtr:id><gtr:otherNames>Ellis J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CE6476859C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E53FF810-93A2-453C-A0E4-44E58EC87AC0</gtr:id><gtr:title>Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcc2284555def528ab993e8adea04d60"><gtr:id>bcc2284555def528ab993e8adea04d60</gtr:id><gtr:otherNames>Xu TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>F9A8DFE0F11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDD03F41-A121-41CB-821C-C84BC6382461</gtr:id><gtr:title>Allosteric modulation of heterodimeric G-protein-coupled receptors.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>FED7F00FB4A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFF617F3-F90F-4B22-ADA3-5C3D2F2F77E6</gtr:id><gtr:title>Chapter 10. Hetero-oligomerization of chemokine receptors.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73b3182f36ddeeed56c38bfb0a425bcc"><gtr:id>73b3182f36ddeeed56c38bfb0a425bcc</gtr:id><gtr:otherNames>Appelbe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>5229315AABB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02F845CC-23FC-4662-A0E0-425F7B22A57C</gtr:id><gtr:title>Building a new conceptual framework for receptor heteromers.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da94eb0da32979e66e69c2d6e3909000"><gtr:id>da94eb0da32979e66e69c2d6e3909000</gtr:id><gtr:otherNames>Ferr? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>EE4EEF82EA0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>249427BA-2537-4322-9117-A45B3AD47E28</gtr:id><gtr:title>The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/007b27bf0d80b1a0eb2b339032484e9c"><gtr:id>007b27bf0d80b1a0eb2b339032484e9c</gtr:id><gtr:otherNames>Lopez-Gimenez JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>0D448E3B463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B08A08DA-112F-4E8C-B097-EE63A10D58B4</gtr:id><gtr:title>BRET analysis of GPCR oligomerization: newer does not mean better.</gtr:title><gtr:parentPublicationTitle>Nature methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69b6a8443b24d38df4f25f4f0b319b3a"><gtr:id>69b6a8443b24d38df4f25f4f0b319b3a</gtr:id><gtr:otherNames>Bouvier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1548-7091</gtr:issn><gtr:outcomeId>9BB121E18A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C6A381C-FDD9-4365-861A-019D15D15A38</gtr:id><gtr:title>Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfe83ef029eb561882dad7311aebc837"><gtr:id>dfe83ef029eb561882dad7311aebc837</gtr:id><gtr:otherNames>Canals M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>7E7CFED89F4</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9811527</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>